Boone Capital Management LLC Boosts Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Boone Capital Management LLC raised its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 8.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 209,853 shares of the biotechnology company's stock after acquiring an additional 16,964 shares during the quarter. Viking Therapeutics makes up about 2.8% of Boone Capital Management LLC's holdings, making the stock its 13th largest holding. Boone Capital Management LLC owned 0.19% of Viking Therapeutics worth $8,444,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new position in Viking Therapeutics in the 4th quarter valued at $51,464,000. Massachusetts Financial Services Co. MA grew its holdings in shares of Viking Therapeutics by 446.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,357,241 shares of the biotechnology company's stock worth $54,615,000 after buying an additional 1,108,972 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of Viking Therapeutics by 228.5% in the fourth quarter. Ameriprise Financial Inc. now owns 1,479,596 shares of the biotechnology company's stock valued at $59,540,000 after buying an additional 1,029,125 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Viking Therapeutics in the fourth quarter worth about $24,888,000. Finally, Braidwell LP boosted its position in Viking Therapeutics by 27.9% during the fourth quarter. Braidwell LP now owns 1,479,666 shares of the biotechnology company's stock worth $59,542,000 after acquiring an additional 322,689 shares during the last quarter. Hedge funds and other institutional investors own 76.03% of the company's stock.

Viking Therapeutics Stock Performance

Viking Therapeutics stock opened at $29.49 on Tuesday. The company has a market capitalization of $3.31 billion, a PE ratio of -29.49 and a beta of 0.75. Viking Therapeutics, Inc. has a fifty-two week low of $18.92 and a fifty-two week high of $81.86. The firm has a 50 day moving average price of $26.21 and a 200 day moving average price of $38.78.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The business's quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. As a group, equities research analysts forecast that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Insider Buying and Selling

In other Viking Therapeutics news, Director Sarah Kathryn Rouan purchased 1,240 shares of the company's stock in a transaction on Monday, March 31st. The stock was acquired at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the purchase, the director now directly owns 1,240 shares in the company, valued at approximately $29,946. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

VKTX has been the topic of a number of research reports. The Goldman Sachs Group began coverage on shares of Viking Therapeutics in a research note on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 target price on the stock. Citigroup assumed coverage on Viking Therapeutics in a research report on Friday, February 7th. They set a "neutral" rating and a $38.00 price objective on the stock. Scotiabank initiated coverage on Viking Therapeutics in a report on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 target price for the company. B. Riley reiterated a "buy" rating and set a $96.00 price target (down previously from $109.00) on shares of Viking Therapeutics in a report on Friday, February 7th. Finally, Truist Financial reissued a "buy" rating and issued a $75.00 price objective (down previously from $95.00) on shares of Viking Therapeutics in a report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Viking Therapeutics has an average rating of "Moderate Buy" and an average target price of $87.15.

Viking Therapeutics Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.